Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

BACKGROUND: This is a placebo-controlled multi-national trial of roluperidone, a compound with antagonist properties for 5-HT(2A), sigma(2), and α(1A)-adrenergic receptors, targeting negative symptoms in patients with schizophrenia. This trial follows a previous trial that demonstrated roluperidone...

Descripción completa

Detalles Bibliográficos
Autores principales: Davidson, Michael, Saoud, Jay, Staner, Corinne, Noel, Nadine, Werner, Sandra, Luthringer, Elisabeth, Walling, David, Weiser, Mark, Harvey, Philip D, Strauss, Gregory P, Luthringer, Remy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Regular Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077422/
https://www.ncbi.nlm.nih.gov/pubmed/35211743
http://dx.doi.org/10.1093/schbul/sbac013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077422/
https://www.ncbi.nlm.nih.gov/pubmed/35211743
http://dx.doi.org/10.1093/schbul/sbac013

Ejemplares similares